Alcobra names new board member
This article was originally published in Scrip
Tel Aviv, Israel-based Alcobra, an emerging pharmaceutical company focused on the development of new medications for cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, has appointed Dr Joao Siffert to its board of directors. Dr Siffert is currently executive vice-president of R&D and chief medical officer of Avanir Pharmaceuticals (a subsidiary of Otsuka Pharmaceutical).
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.